Exelixis Inc Total Contract Liability
Exelixis Inc (EXEL) had Total Contract Liability of $5.70 million as of 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-08-05
- 2026-07-03: Contract with Customer, Liability $5.70M.
- 2026-04-03: Contract with Customer, Liability $6.32M.
- 2026-01-02: Contract with Customer, Liability $7.23M.
- 2025-10-03: Contract with Customer, Liability $3.83M.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2026-07-03 | $5.70M 10-Q · filed 2026-08-05 | |
| 2026-04-03 | $6.32M 10-Q · filed 2026-05-05 | |
| 2026-01-02 | $7.23M 10-Q · filed 2026-08-05 | |
| 2025-10-03 | $3.83M 10-Q · filed 2025-11-04 | |
| 2025-07-04 | $4.79M 10-Q · filed 2025-07-28 | |
| 2025-04-04 | $5.96M 10-Q · filed 2025-05-13 | |
| 2025-01-03 | $6.13M 10-K · filed 2026-02-10 | |
| 2024-09-27 | $7.20M 10-Q · filed 2024-10-29 | |
| 2024-06-28 | $7.86M 10-Q · filed 2024-08-06 | |
| 2024-03-29 | $8.98M 10-Q · filed 2024-04-30 | |
| 2023-12-29 | $10.93M 10-K · filed 2025-02-11 | |
| 2023-09-29 | $13.35M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $13.53M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $13.36M 10-Q · filed 2023-05-09 | |
| 2022-12-30 | $14.07M 10-K · filed 2024-02-06 | |
| 2022-09-30 | $13.42M 10-Q · filed 2022-11-01 | |
| 2022-07-01 | $14.72M 10-Q · filed 2022-08-09 | |
| 2022-04-01 | $15.38M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $16.55M 10-K · filed 2023-02-07 | |
| 2021-10-01 | $16.98M 10-Q · filed 2021-11-02 | |
| 2021-07-02 | $14.89M 10-Q · filed 2021-08-05 | |
| 2021-04-02 | $18.97M 10-Q · filed 2021-05-06 | |
| 2021-01-01 | $5.54M 10-K · filed 2022-02-18 | |
| 2020-10-02 | $10.60M 10-Q · filed 2020-11-05 | |
| 2020-07-03 | $16.30M 10-Q · filed 2020-08-06 | |
| 2020-04-03 | $15.40M 10-Q · filed 2020-05-05 | |
| 2020-01-03 | $6.60M 10-K · filed 2021-02-11 | $6.60M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |